SCHEMBL7135503

SCHEMBL7135503

CC(CCNC(=O)Cc1ccncc1)CC(=O)NCC(=O)C(O)CCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
GAA P10253 2/20 0.46
MAPT P10636 1/20 0.46
CNR1 P21554 3/20 0.44
HPGD P15428 2/20 0.43
EPHX2 P34913 1/20 0.43
KMT2A Q03164 2/20 0.41
TRPV1 Q8NER1 2/20 0.41
LMNA P02545 1/20 0.41
PKM P14618 1/20 0.41
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA5A P35218 1/20 0.40
CA7 P43166 1/20 0.40
CA5B Q9Y2D0 1/20 0.40
CNR2 P34972 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 1/20 0.39
RAB9A P51151 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7137518 0.94 CNR1 (0.49) ALDH1A1GAACNR1HPGDEPHX2
SCHEMBL7136859 0.90 EPHX2 (0.56) ALDH1A1CNR1HPGDEPHX2KMT2A
SCHEMBL7139612 0.87 ALDH1A1 (0.43) ALDH1A1GAAMAPTCNR1HPGD
SCHEMBL7139406 0.85 LMNA (0.51) ALDH1A1GAAHPGDKMT2ALMNA
SCHEMBL7136755 0.84 LMNA (0.47) ALDH1A1CNR1HPGDEPHX2KMT2A
SCHEMBL7131854 0.84 KMT2A (0.44) ALDH1A1HPGDKMT2ALMNAPKM
SCHEMBL7136761 0.81 EPHX1 (0.50) ALDH1A1MAPTHPGDEPHX2KMT2A
SCHEMBL7133782 0.81 PTPN1 (0.49) ALDH1A1HPGDKMT2ALMNAPKM
SCHEMBL7137508 0.81 LMNA (0.44) ALDH1A1MAPTHPGDKMT2ALMNA
SCHEMBL7800995 0.80 ALDH1A1 (0.42) ALDH1A1GAAMAPTCNR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030092634-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2003-05-15 US disclosed
US-6506733-B1 Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. AXYS PHARMACEUTICALS, INC. 2003-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092634-A1 Novel compounds and compositions as protease inhibitors SERPINB1, HPN, CTRL ALDH1A1 3641/4885GAA 330/4885MAPT 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.